Hepsulfam (BioDeep_00000179711)
human metabolite blood metabolite Volatile Flavor Compounds
代谢物信息卡片
化学式: C7H18N2O6S2 (290.0606248)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(blood) 97.5%
分子结构信息
SMILES: C(CCCOS(=O)(=O)N)CCCOS(=O)(=O)N
InChI: InChI=1S/C7H18N2O6S2/c8-16(10,11)14-6-4-2-1-3-5-7-15-17(9,12)13/h1-7H2,(H2,8,10,11)(H2,9,12,13)
描述信息
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D009676 - Noxae > D000477 - Alkylating Agents
同义名列表
数据库引用编号
5 个数据库交叉引用编号
- PubChem: 100606
- HMDB: HMDB0253091
- ChEMBL: CHEMBL182440
- chemspider: 90900
- CAS: 96892-57-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:
- PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。
文献列表
- L A Harker, U M Marzec, A B Kelly, E Cheung, A Tomer, J L Nichol, S R Hanson, R B Stead. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
Blood.
1997 Jan; 89(1):155-65. doi:
NULL
. [PMID: 8978288] - M V Marshall, K D Carey, D D Von Hoff, J G Kuhn. Hepsulfam distribution in blood, plasma and cerebrospinal fluid of baboons.
Investigational new drugs.
1995; 13(1):33-6. doi:
10.1007/bf02614217
. [PMID: 7499105] - R A Larson, R B Geller, L Janisch, J Milton, L B Grochow, M J Ratain. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
Cancer chemotherapy and pharmacology.
1995; 36(3):204-10. doi:
10.1007/bf00685847
. [PMID: 7781139] - M V Marshall, M H Marshall, D R Degen, G D Roodman, J G Kuhn, M E Ross, D D Von Hoff. In vitro cytotoxicity of hepsulfam against human tumor cell lines and primary human tumor colony forming units.
Stem cells (Dayton, Ohio).
1993 Jan; 11(1):62-9. doi:
10.1002/stem.5530110111
. [PMID: 8457783] - P M Ravdin, K A Havlin, M V Marshall, T D Brown, J M Koeller, J G Kuhn, G Rodriguez, D D Von Hoff. A phase I clinical and pharmacokinetic trial of hepsulfam.
Cancer research.
1991 Dec; 51(23 Pt 1):6268-72. doi:
NULL
. [PMID: 1933887] - C B Hendricks, L B Grochow, E K Rowinsky, A A Forastiere, W P McGuire, D S Ettinger, S Sartorius, B Lubejko, R C Donehower. Phase I and pharmacokinetic study of hepsulfam (NSC 329680).
Cancer research.
1991 Nov; 51(21):5781-5. doi:
NULL
. [PMID: 1933848] - J I Brodfuehrer, G Powis. Gas chromatographic assay for the new antitumor agent sulfamic acid diester (NSC 329680) and its stability in buffer, blood and plasma.
Journal of chromatography.
1988 Jun; 427(2):247-55. doi:
10.1016/0378-4347(88)80127-0
. [PMID: 3410909] - J I Brodfuehrer, T J Wilke, G Powis. Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog.
Cancer chemotherapy and pharmacology.
1988; 22(2):120-5. doi:
10.1007/bf00257308
. [PMID: 3409442]